Novartis AG (NVS)
| Market Cap | 311.29B +49.4% |
| Revenue (ttm) | 56.67B +9.6% |
| Net Income | 13.98B +17.1% |
| EPS | 7.15 +21.8% |
| Shares Out | 1.91B |
| PE Ratio | 22.69 |
| Forward PE | 18.07 |
| Dividend | $3.10 (1.91%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 212,783 |
| Open | 162.67 |
| Previous Close | 163.92 |
| Day's Range | 162.01 - 162.85 |
| 52-Week Range | 97.72 - 167.86 |
| Beta | 0.46 |
| Analysts | Hold |
| Price Target | 118.00 (-27.34%) |
| Earnings Date | Feb 4, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $118.0, which is a decrease of -27.34% from the latest price.
News
Trump meets Novartis CEO, says drugmaker building 11 US plants
U.S. President Donald Trump said he met Vas Narasimhan, the chief executive officer of Swiss drugmaker Novartis , at the White House on Wednesday.
Novartis to sell entire 71% stake in Indian unit to consortium of WaveRise Investments
Swiss pharmaceutical firm Novartis said on Friday that it would sell its entire 70.68% stake in its listed Indian unit to a consortium of WaveRise Investments, ChrysCapital and Two Infinity Partners.
Unnatural Products, Novartis sign license deal worth up to $1.7 billion for cardiovascular program
Unnatural Products said on Wednesday it has signed a licensing agreement with Novartis to develop macrocyclic peptide-based therapies for a cardiovascular program.
Unnatural Products Announces Licensing Agreement with Novartis to Develop Macrocyclic Peptide Therapeutics
SANTA CRUZ, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announ...
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Basel, February 18, 2026 – Novartis today announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU)1. The primary endpoint ...
Novartis Says Vanrafia Drug Slows Kidney Function Decline
The pharma major said that phase 3 trials showed Vanrafia slowed the decline in kidney function for adults with progressive autoimmune kidney disease, IgA nephropathy.
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated ...
Oakmark International Strategy Q4 2025 New Investments And Divestments
Oakmark International Strategy Q4 2025 New Investments And Divestments
Novartis: Value Price, Growth Pipeline
Novartis (NVS) offers a compelling value opportunity with EPS growth, margin expansion, and a robust pipeline at a discounted multiple. NVS is undergoing a slow re-rating, actively buying back shares,...
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead
Swiss pharmaceutical Novartis AG (NYSE: NVS) reported fourth-quarter 2025 results on Wednesday.
Novartis Sales Rise Despite Generic Drug Competition in U.S.
The pharma major said it had strong results in 2025, but guided toward a decline in core operating profit this year.
Novartis expects low single-digit decline in 2026 operating profit
Swiss drugmaker Novartis forecast a decline in 2026 operating profit in the low single-digit percentage range on Wednesday, held back by competition from cheaper copies of established products such as...
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +8% (cc 1 , +8% USD) with core operating income 1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from pr...
Novartis CEO on impact of 'most favored nation' drug pricing
Novartis CEO Vas Narasimham, speaking with CNBC about lowering drug prices, said the focus should be on reducing patient out-of-pocket drug costs, not list or net prices, though believes progress is m...
Novartis CEO Vas Narasimhan: ‘We really should be talking about out-of-pocket costs' in the U.S.
Vas Narasimhan, CEO of Novartis, joins 'Money Movers' to discuss U.S. drug pricing, healthcare, and more.
Novartis CEO: Confident we are shielded from any further U.S. tariffs
Novartis CEO Vas Narasimhan told CNBC in Davos that he believes the Swiss drugmaker is protected from any additional U.S. tariffs on Europe, citing its U.S. manufacturing footprint, inventory levels, ...
Novartis could have a U.S. deal that shields it from tariffs, CEO tells CNBC
Swiss pharmaceutical giant Novartis expects to "not really" be exposed to tariffs by the middle of the year, CEO Vas Narasimhan told CNBC at Davos. "We also have an agreement with the US government th...
Novartis expects to eliminate US tariff exposure by mid‑2026, CEO tells CNBC
Novartis CEO Vas Narasimhan told CNBC on Tuesday he expects the drugmaker's agreement with the U.S. government and its expanding manufacturing footprint in the country to protect it from potential tar...
Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset
ZHUZHOU, China & BOSTON--(BUSINESS WIRE)--Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based as...
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novartis eyes more bolt-on acquisitions, CEO says
Novartis will continue to do bolt-on deals and its capital allocation priorities remain unchanged, CEO Vasant Narasimhan said at a major industry conference that kicked off on Monday in San Francisco.
SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs
Swiss drugmaker Novartis has signed a licensing deal worth nearly $1.7 billion with privately held SciNeuro Pharmaceuticals to develop potential antibody treatments for Alzheimer's disease, the biotec...
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
Basel, January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida....
Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...